AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30397015 — intervention group
Group type: EXPERIMENTAL
Intervention: AURAS‐AF software tool for risk assessment and reminders during consultations
Number of subjects: 476
Study 30397015 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with clinicians and patients
Number of subjects: 476
Study 27137756 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil 2.5 μg
Number of subjects: 180
Study 27137756 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil 5 μg
Number of subjects: 180
Study 27137756 — intervention group
Group type: COMPARATOR
Intervention: fentanyl 25 μg
Number of subjects: 180
Study 24835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulary applications for new drugs or new indications (95 applications)
Number of subjects: 120
Study 24835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications reviewed by statewide medicines advisory committee or hospital pharmacist (45 applications)
Number of subjects: 120
Study 24835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications including randomised controlled trials (37 applications)
Number of subjects: 120
Study 24835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications including case series (36 applications)
Number of subjects: 120
Study 24835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications including product information (34 applications)
Number of subjects: 120
Study 24835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications including narrative reviews (29 applications)
Number of subjects: 120
Study 24835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications including systematic review or meta-analysis (14 applications)
Number of subjects: 120
Study 24835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications with a declared conflict of interest (10 applications)
Number of subjects: 120
Study 24835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of risk of bias of supporting studies
Number of subjects: 120
Study 22540419 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based toothbrushing programme (SBTB) for 2 years
Number of subjects: 150
Study 22540419 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-SBTB)
Number of subjects: 150
Study 20298560 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised physical activity feedback ('simple')
Number of subjects: 500
Study 20298560 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised physical activity feedback ('visualised')
Number of subjects: 500
Study 20298560 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised physical activity feedback ('contextualised')
Number of subjects: 500
Study 20298560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 500
Study 18049317 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental report using the Diagnostic Interview Schedule for Children (DISC)
Number of subjects: 1070
Study 18049317 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD medication use
Number of subjects: 1070
Study 16259507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum and motivational interviewing
Number of subjects: 813
Study 16259507 — intervention group
Group type: COMPARATOR
Intervention: Health fairs for recruitment
Number of subjects: 813
Study 11834115 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (0.3 g x kg(‐1) x d(‐1)) with 1-minute recovery interval
Number of subjects: 30
Study 11834115 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (0.3 g x kg(‐1) x d(‐1)) with 3-minute recovery interval
Number of subjects: 30
Study 11834115 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with 6-minute recovery interval
Number of subjects: 30
Study 11834115 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with 1-minute recovery interval
Number of subjects: 30
Study 11798639 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Number of subjects: 75
Study 11798639 — intervention group
Group type: COMPARATOR
Intervention: All-trans retinoic acid
Number of subjects: 75
Study 7743615 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (rTPA)
Number of subjects: 2634
Study 7743615 — intervention group
Group type: COMPARATOR
Intervention: Invasive post-lytic management strategy
Number of subjects: 2634
Study 7743615 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave infarct
Number of subjects: 2634
Study 30605708 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on 10Hz rTMS treatment (20 times)
Number of subjects: 90
Study 30605708 — intervention group
Group type: COMPARATOR
Intervention: Routine addiction rehabilitation
Number of subjects: 90
Study 28864955 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal (TEP) repair
Number of subjects: 98
Study 28864955 — intervention group
Group type: COMPARATOR
Intervention: Open inguinal hernia (Shouldice) repair
Number of subjects: 98
Study 25886569 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced motivational interviewing (MI) intervention delivered in group or individual formats, 10 sessions plus an introductory session over one year.
Number of subjects: 1704
Study 25886569 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1704
Study 25886569 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced MI intervention
Number of subjects: 1704
Study 23759326 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening every 4 years with PSA level cut-off ≥ 3.0 ng/ml as biopsy indication (S-arm)
Number of subjects: 42376
Study 23759326 — intervention group
Group type: COMPARATOR
Intervention: No intervention (C-arm)
Number of subjects: 42376
Study 21342773 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine pretreatment (2.45 mg kg⁻¹ over 10 min)
Number of subjects: 82
Study 21342773 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine pretreatment
Number of subjects: 82
Study 21342773 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 82
Study 18539916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (gliclazide modified release plus other drugs)
Number of subjects: 11140
Study 18539916 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study 16019923 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 385
Study 12768462 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (1332 mg daily)
Number of subjects: 26
Study 12768462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 10228313 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 125
Study 10228313 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 125
Study 8898507 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 25 micrograms/hr
Number of subjects: 35
Study 8898507 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 50 micrograms/hr
Number of subjects: 35
Study 8898507 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 35
Study 1725280 — intervention group
Group type: EXPERIMENTAL
Intervention: PPF (DDP 100 mg/m2 + pingyangmycin + 5‐FU) regimen plus radiotherapy
Number of subjects: 64
Study 1725280 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 64
Study 6654768 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and consultation package designed to increase the reinforcing ambience of the school
Number of subjects: 18
Study 30678662 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of student performance using the APP tool at 'not adequate' level
Number of subjects: 153
Study 30678662 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of student performance using the APP tool at 'good/excellent' level
Number of subjects: 153
Study 30678662 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of student performance using the APP tool at 'adequate' level
Number of subjects: 153
Study 30678662 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiating 'not adequate' from 'adequate' or better
Number of subjects: 153
Study 30678662 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment across clinical areas for 'not adequate' and 'good/excellent' levels
Number of subjects: 153
Study 30678662 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment across clinical areas for 'adequate' level
Number of subjects: 153
Study 29693483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (n=44)
Number of subjects: 132
Study 29693483 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (n=47)
Number of subjects: 132
Study 29693483 — intervention group
Group type: COMPARATOR
Intervention: No additional training (n=41)
Number of subjects: 132
Study 27854209 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceneuramic acid extended-release (Ace-ER) 6g/day
Number of subjects: 47
Study 27854209 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 6g/day group after crossover
Number of subjects: 47
Study 27854209 — intervention group
Group type: COMPARATOR
Intervention: Aceneuramic acid extended-release (Ace-ER)
Number of subjects: 47
Study 27854209 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 6g/day group
Number of subjects: 47
Study 24559216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive combination treatment strategies (ICTS) for early RA
Number of subjects: 32
Study 24559216 — intervention group
Group type: COMPARATOR
Intervention: Conventional disease-modifying anti-rheumatic drugs (DMARDs) plus step-down glucocorticoids (GCs)
Number of subjects: 32
Study 22759883 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance training (RT)
Number of subjects: 41
Study 22759883 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 41
Study 22759883 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care
Number of subjects: 41
Study 20639252 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial faecal occult blood testing (FOBT) screening
Number of subjects: 78708
Study 20639252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 78708
Study 20639252 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants receiving negative test results
Number of subjects: 78708
Study 20639252 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in screening
Number of subjects: 78708
Study 20639252 — intervention group
Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 78708
Study 20639252 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants receiving positive test results
Number of subjects: 78708
Study 18692637 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (125 microg/kg)
Number of subjects: 116
Study 18692637 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (250 microg/kg)
Number of subjects: 116
Study 18692637 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (500 microg/kg)
Number of subjects: 116
Study 18692637 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (all doses)
Number of subjects: 116
Study 15778268 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg kg(‐1) and glycopyrrolate 0.01 mg kg(‐1)
Number of subjects: 40
Study 15778268 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate alone
Number of subjects: 40
Study 12501883 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gemifloxacin 320 mg once daily (7-14 days)
Number of subjects: 345
Study 12501883 — intervention group
Group type: COMPARATOR
Intervention: IV ceftriaxone 2 g once daily (1-7 days) followed by oral cefuroxime 500 mg twice daily (1-13 days)
Number of subjects: 345
Study 12501883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 345
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor with oxytocin
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor with prostaglandins
Number of subjects: 5041
Study 10362176 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery in Israel
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery in Australia
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor lasting more than 12 hours
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor lasting 6-12 hours
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous cesarean delivery
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical chorioamnionitis
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fetal heart rate monitoring
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight of at least 4000 g
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age of at least 35 years
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent period of at least 12 hours
Number of subjects: 5041
Study 10362176 — intervention group
Group type: EXPERIMENTAL
Intervention: Meconium staining
Number of subjects: 5041
Study 8746573 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless scleral tunnel frown incision
Number of subjects: 200
Study 8746573 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral tunnel frown incision with a horizontal suture
Number of subjects: 200
Study 8746573 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral tunnel frown incision with both a horizontal and a running suture
Number of subjects: 200
Study 8746573 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior limbal acute beveled cataract incision with a running suture
Number of subjects: 200
Study 2183645 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPPT) - 1 g intravenously
Number of subjects: 18
Study 2183645 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone
Number of subjects: 18
Study 7453160 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic training (IT)
Number of subjects: 33
Study 7453160 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training (IK)
Number of subjects: 33
Study 7453160 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 30244533 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐SES (Orsiro sirolimus‐eluting stent)
Number of subjects: 2525
Study 30244533 — intervention group
Group type: COMPARATOR
Intervention: N‐BES (Nobori biolimus‐eluting stent)
Number of subjects: 2525
Study 30244533 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐SES
Number of subjects: 2525
Study 30244533 — intervention group
Group type: COMPARATOR
Intervention: N‐BES
Number of subjects: 2525
Study 29143428 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 μg/day + Calcium 500 mg/day
Number of subjects: 95
Study 29143428 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Calcium 500 mg/day
Number of subjects: 95
Study 27764706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin for 14 days
Number of subjects: 105
Study 27764706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin for 1 day
Number of subjects: 105
Study 27764706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 105
Study 24559249 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised cigarette packaging
Number of subjects: 98
Study 24559249 — intervention group
Group type: COMPARATOR
Intervention: Branded cigarette packaging
Number of subjects: 98
Study 24559249 — intervention group
Group type: COMPARATOR
Intervention: Own cigarette package
Number of subjects: 98
Study 22460260 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on ethylene‐vinyl acetate (EVA) bench model with feedback of instructors
Number of subjects: 16
Study 22460260 — intervention group
Group type: COMPARATOR
Intervention: Faculty-directed training based on books and instructional videos (Control)
Number of subjects: 16
Study 20487610 — intervention group
Group type: EXPERIMENTAL
Intervention: Household symptom screening and spot sputum collection (Arm 1)
Number of subjects: 193
Study 20487610 — intervention group
Group type: COMPARATOR
Intervention: Distribution of an educational pamphlet (Arm 2)
Number of subjects: 193
Study 18790208 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 118
Study 16911730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure therapy (CET)
Number of subjects: 0
Study 16911730 — intervention group
Group type: COMPARATOR
Intervention: Placebo psychotherapy
Number of subjects: 0
Study 16911730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment attentional bias
Number of subjects: 0
Study 12021419 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12 months of home‐based exercise counseling, at least four exercise sessions per week, for at least 30 minutes per session)
Number of subjects: 100
Study 12021419 — intervention group
Group type: COMPARATOR
Intervention: Attention control (nutrition education)
Number of subjects: 100
Study 10588819 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (0.3 mg)
Number of subjects: 14
Study 10588819 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study 8738728 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (40 mg, orally; n = 12)
Number of subjects: 22
Study 8738728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 22
Study 1820892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 2 mg idaverine
Number of subjects: 12
Study 1820892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1 mg idaverine
Number of subjects: 12
Study 1820892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 2 mg idaverine
Number of subjects: 12
Study 1820892 — intervention group
Group type: EXPERIMENTAL
Intervention: Idaverine (all doses)
Number of subjects: 12
Study 6357018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure breathing (IPPB) therapy
Number of subjects: 985
Study 6357018 — intervention group
Group type: COMPARATOR
Intervention: Compressor nebulizer therapy
Number of subjects: 985
Study 29362242 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative Grading of Recommendations Assessment, Development and Evaluation (GRADE) SoF table
Number of subjects: 0
Study 29362242 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based Practice Center SoF table
Number of subjects: 0
Study 29362242 — intervention group
Group type: COMPARATOR
Intervention: Current GRADE SoF table
Number of subjects: 0
Study 27157843 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bimatoprost ocular insert
Number of subjects: 130
Study 27157843 — intervention group
Group type: COMPARATOR
Intervention: Timolol (0.5% solution) eye drops
Number of subjects: 130
Study 27157843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost ocular insert
Number of subjects: 130
Study 27157843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost ocular insert and Timolol
Number of subjects: 130
Study 25628069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 37
Study 25628069 — intervention group
Group type: COMPARATOR
Intervention: Control group (preserved LV function)
Number of subjects: 37
Study 25628069 — intervention group
Group type: COMPARATOR
Intervention: Heart failure patients (without CRT)
Number of subjects: 37
Study 23808510 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (alkalinised lignocaine)
Number of subjects: 300
Study 23808510 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L (lignocaine)
Number of subjects: 300
Study 23808510 — intervention group
Group type: COMPARATOR
Intervention: Group S (control, normal saline)
Number of subjects: 300
Study 21088639 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on child passenger safety
Number of subjects: 139
Study 21088639 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no video)
Number of subjects: 139
Study 18988910 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1644
Study 16479368 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 0
Study 16479368 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy
Number of subjects: 0
Study 14967869 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO) 1.0 g x kg body mass(-1)
Number of subjects: 9
Study 14967869 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 9
Study 14967869 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO)
Number of subjects: 9
Study 11069375 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant mitozantrone chemotherapy
Number of subjects: 96
Study 11069375 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy alone
Number of subjects: 96
Study 8686962 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg 5‐ISMN once daily for one week followed by 60 mg 5‐ISMN once daily for one week
Number of subjects: 89
Study 8686962 — intervention group
Group type: COMPARATOR
Intervention: 60 mg 5‐ISMN once daily for two weeks
Number of subjects: 89
Study 8686962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosage regimens
Number of subjects: 89
Study 8686962 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting on a low dosage
Number of subjects: 89
Study 8686962 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 89